Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Rucaparib + Ramucirumab +/- Nivolumab for Stomach and Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Olathe, Kansas
This trial is for people with advanced stomach, gastroesophageal, or esophageal cancer who have failed initial chemotherapy. The goal is to see if Rucaparib plus Ramucirumab with or without Nivolumab is more effective than what has been reported for Ramucirumab alone. The trial will have a phase 1 component to determine the recommended dosage, and a phase 2 component to compare the two treatment groups.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service